Mirza MR, Monk BJ, Herrstedt J et al. Oza AM, Tinker AV, Oaknin A et al. In cooperation with the European Society of Medical Oncology (ESMO) and encompassing the existing ESGO Recommendations for Ovarian Cancer Surgery, ESGO developed consensus recommendations for the management of ovarian cancer. MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23, Words highlighted in bold are defined in the ovarian cancer glossary. Coleman RL, Oza AM, Lorusso D et al. N Engl J Med 2016; 375: 2154–2164. The medical information described in this document is based on ESMO clinical practice guidelines for newly diagnosed and relapsed epithelial ovarian cancer. This site uses cookies. This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. ESGO 2017 congress, November 4-7, 2017 in Vienna Austria. To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive. Friedlander M, Matulonis U, Gourley C et al. The consensus conference on ovarian cancer management initiated by the European Society of Gynaecological Oncology (ESGO) together with the European Society of … For patients with recurrent platinum-sensitive ovarian cancer and a BRCA mutation unable to receive platinum-based therapy, rucaparib monotherapy is an option [III, A]. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. The EMA has also approved rucaparib monotherapy for patients with a germline or somatic BRCA mutation who have received at least two lines of therapy and are unable to receive platinum-based treatment. You are scheduled to receive chemotherapy for a low-grade, You may receive additional treatments such as, Treatment with steroids may be reduced or stopped as they can suppress your, You may receive maintenance therapy with a, Non-platinum-based chemotherapy is considered a low priority and will only be given after careful consideration of the potential benefits in light of the risk of severe illness following, If you have a confirmed diagnosis of ovarian cancer and are currently participating in a. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Ovarian Cancer Guidelines ESGO guidelines for the management of ovarian cancer surgery, including quality indicators and the process to qualify centers for ovarian cancer surgery certification. For rucaparib, in the intention to treat population, the HR is 0.36 (95% CI 0.30–0.45) with a median PFS of 10.8 versus 5.4 months [2]. ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals, Collaborating on registries, studies and surveys, Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Translational Research and Precision Medicine Working Group, Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group. Cancer Patient Management During the COVID-19 Pandemic, Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the COVID-19 era, Haematological malignancies: Hodgkin lymphoma in the COVID-19 era, Haematological malignancies: Indolent B-NHL in the COVID-19 era, Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO-ESO Courses on Medical Oncology for Medical Students.
Email: esgo-guidelines@esgomail.org See Appendix for members of the ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. Receive information and updates on ESMO’s scientific and educational resources, events, members activities. The olaparib tablet approval for non BRCA-mutated tumours is based on the subgroup analysis of Study 19 with a HR 0.54 (95% CI 0.34-0.85) and a median PFS of 7.4 versus 5.5 months [1]. Ledermann JA, Raja FA, Fotopoulou C et al. Maintenance therapy with a PARP inhibitor (olaparib, niraparib or rucaparib) following a response to platinum-based therapy in patients with recurrent platinum-sensitive high-grade ovarian cancer is a new standard of care option, irrespective of BRCA status [I, A]. Cancer Patient Management During the COVID-19 Pandemic.
Ann Oncol 2019; 30: 672–705. Your outpatient appointment may be a high priority if: Your outpatient appointment may be a medium priority if: Your outpatient appointment may be a low priority if: Your appointment may be a high priority if: Your appointment may be a medium priority if: Your appointment may be a low priority if: Receive information and updates on ESMO’s scientific and educational resources, events, members activities. Following the results of the first randomised maintenance trial with olaparib demonstrating a significant improvement in progression-free survival (PFS), particularly in patients with a BRCA mutation [1], further data has emerged and three other phase III trials with other poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have been conducted [2-4]. This was based on a combined analysis of two phase II trials, ARIEL2 and Study 10, demonstrating a response rate of 53.8% (95% CI 43.8–63.5) with 8.5% and 45.3% of patients achieving a complete and partial responses, respectively.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23, Latest enhanced and revised set of guidelines.
China Finance Ministry Tariff List, Alan Jones Sky News Podcast, Alfie Full Movie, Bodybuilding Appetite, Ff14 Hairstyles Quest, England 1990 Shirt Blue Umbro, The Pomegranate Seeds Proserpina, The Journey Is The Destination Full Movie, Blind Man's Bluff Poker, Katharine Mcphee And David Foster, Corvidae Pronunciation, Antique Sling Blade Value, Reformation Wedding Dress, World Food Days 2019, Moore V Dempsey Oyez, Lake Paintingseasy, Not Rapper Real Name, Where Is Juan Felipe Herrera From, Cornelius Janssens Portrait Of A Gentleman, Article 2 Quizlet, Amd Ryzen Threadripper 3970x Motherboard, Is Tb Contagious, How Were The Initial Sit-ins During The Birmingham Campaign Of 1963 Received?, 4music Enter Shikari, Prince Edward The Crown, Paul Evans Sofa, Greek Goddess Of Pain, St Ives Weather Forecast 14 Days, Poetry By Heart Logo, Best Place To Live In Cornwall For Families, Vibrio Cholerae Pathogenesis Slideshare, William Wordsworth Death, Monash Research, Napoleon Bonaparte Painting, Homemade Storybook Costumes, Jlo Diet Shake, Sierra Meaning, Ted Terry Election, Is E Coli Contagious, Corynebacterium Diphtheriae Treatment, Sarcastic Female Monologues From Plays, Flowers In A Glass Dome, Prints Made To Look Like Oil Paintings, S Iswaran Kay Mary Taylor, Razalean Gnc, Hib Meaning In Tamil, Hell, Michigan Owner, Motiongate Tickets 29 Aed, Nurse Intervention For Tuberculosis, 200 Calorie Hiit Workout, Personification In Seven Ages Of Man, Between Rounds Owner, Lady Clare 1357 France, Red Vs Blue Fortnite Hacks, St Etienne, Caen, Metropolitan Museum Of Art Fragonard, Classification Of Ocean Waves,
